Shensong Yangxin Capsule

Shensong Yangxin Capsule

A new patent drug for arrhythmia——Shensong Yangxin capsules

Shensong Yangxin capsules——Integrated regulation and effect ion on both fast and slow diseases

Arrhythmia seriously threats human health and life. There was no new drug for the treatment of arrhythmia in western medicine over the past 20 years. Existing arrhythmia western medicines have the bigger side effect and may increase mortality even. Clinical evidence-based medicine research has confirmed that Shensong Yangxin Capsule can effectively treat premature beat and paroxysmal atrial fibrillation, improve slow ventricular rate, significantly relieve clinical symptoms such as palpitation, shortness of breath, and insomnia, and has no adverse cardiac reactions. It has been praised by the majority of doctors and patients, and become the leading brand for the treatment of arrhythmia in China.

With 1,476 cases included, the clinical evidence-based medicine research results confirmed that:

Participating Hospitals: 32 AAA hospitals led by Beijing Fuwai Hospital, Beijing Chaoyang Hospital and the First Affiliated Hospital of Nanjing Medical University

Fast-type diseases

● 859 cases of premature ventricular beat: The total effective rate of Shensong Yangxin was 65.8%, which was better than that of Mexiletine (50.7%)

● 349 cases of paroxysmal atrial fibrillation: Shensong Yangxin and Propafenone had the similar effect, 62.3% vs 58.6%

● Shensong Yangxin had better improvement of symptoms than Propafenone.

Regulate

Slow-type diseases

268 cases of slow-type bradyarrhythmia: The total effective rate of Shensong Yangxin was 63.5%, and the average ventricular rate was increased by 7.09 beats / min. The lower the ventricular rate, the more obvious the improvement.

Inclusion of Shensong Yangxin Capsules in Medication Guidelines and Expert Consensus

Chinese Medical Association "Consensus of Chinese Experts on Ventricular Arrhythmias" 2020

National Health Commission "Atrial Fibrillation: Current Understanding and Treatment Recommendations" 2018

Chinese Association of Rehabilitation Medicine "Consensus of Chinese Experts on Heart Rehabilitation for Atrial Fibrillation Patients" 2021

Consensus of Experts on the Diagnosis and Treatment of Multidisciplinary Microvascular Diseases in China by the Chinese Geriatric Association in 2020

Expert Committee of China Atrial Fibrillation Center Alliance, "Blue Book on Prevention and Treatment of Atrial Fibrillation in China" (2021)

Recommended medication in the "Guidelines for Reasonable Use of Arrhythmias" issued by the National Health Commission (2016)

Medication for Arrhythmias in the Journal of Internal Medicine by the National Health Commission (2018)

The only drug proved by evidence-based medicine to treat premature beat, paroxysmal atrial fibrillation and bradyarrhythmia safely and effectively

The only drug to treat arrhythmia and with integrated regulation of multi-ion and non-ionic channels

The only patent traditional Chinese medicine to treat arrhythmia and winning the Second Prize of National Science and Technology Progress Awards

A. Research has shown that Shensong Yangxin Capsules combined with conventional antiarrhythmic drugs can more effectively reduce ventricular premature beats [1]. The results of randomized, double-blind, multicenter clinical studies have shown that Shensong Yangxin Capsule can reduce ventricular premature beats and alleviate clinical symptoms compared to Meixin or placebo [2-3]. For patients with heart failure and ventricular premature beats, Shensong Yangxin Capsule can reduce the occurrence of ventricular premature beats while also improving the patient's heart function to a certain extent [4]; In patients with sinus bradycardia combined with ventricular premature beats, Shensong Yangxin Capsule can not only reduce the number of ventricular premature beats, but also not increase the risk of sinus bradycardia, and even limited increase the heart rate of sinus bradycardia [5]. For patients with symptomatic ventricular premature beats without or with concomitant structural heart disease, Shensong Yangxin Capsule can be considered for treatment of IIa evidence level A. A domestic multicenter, randomized, double-blind, placebo-controlled clinical trial showed that Shensong Yangxin Capsule can not only reduce the number of ventricular premature beats in patients with congestive heart failure, but also improve heart function and exercise tolerance [4], Consider using Shensong Yangxin Capsules to reduce ventricular premature load and improve cardiac function Level IIa Evidence Level B

--Extract from "2020 Chinese Expert Consensus on Ventricular Arrhythmias"

Editor in Chief: Cardioelectrophysiology and Pacing Branch of the Chinese Medical Association/Cardiology Professional Committee of the Chinese Medical Doctor Association

B. Randomized, double-blind, controlled, and multicenter clinical trials have shown that for paroxysmal atrial fibrillation, the effect of Shensong Yangxin Capsule on maintaining sinus rhythm is equivalent to propafenone, and it has better safety [7]

Suggestion: For paroxysmal atrial fibrillation, Shensong Yangxin Capsules can be used alone (Evidence Level B) or in combination with traditional antiarrhythmic drugs (Evidence Level C)

--Extracted from "Atrial Fibrillation: Current Understanding and Treatment Recommendations G2018"

Chinese Medical Association Cardioelectrophysiology and Pacing Branch/Chinese Medical Doctor Association Cardiology Professional Committee

C. Traditional Chinese patent medicines and simple preparations/preparations such as Shensong Yangxin Capsule [8] and Tongxinluo [9] can improve microcirculation by improving the endothelial function of microvessels, promoting the release of vasodilators and other mechanisms.

--Extracted from the Consensus of Experts on the Diagnosis and Treatment of Multidisciplinary Microvascular Diseases in China

Editor in Chief: Cardiovascular Branch of the Chinese Geriatric Association